Medical Research
(H12)
990 on File
CANCER GENOMICS CONSORTIUM
Financial strength (30%)
91/100
Reliability (20%)
50/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$512K
Total Revenue
$498K
Total Expenses
$487K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
86.9%
Fundraising Efficiency
N/A
Operating Reserve
11.73x
Liability-to-Asset
14.8%
Revenue Diversification
93.3%
Compared with Peers
FY 2025
Compared with 300 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
86.9% | 84.6% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
10.7% | 10.0% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
2.4% | 0.0% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
11.7 mo | 11.7 mo |
P10P90
|
Below median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
14.8% | 0.0% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
93.3% | 92.2% |
P10P90
|
Below median |
|
Surplus margin
Surplus as a share of revenue
|
2.6% | -1.6% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $512K | $498K | $487K | 86.9% | 0 |
| 2023 | $441K | $447K | $507K | 85.3% | 0 |
| 2022 | $472K | $380K | $512K | 90.3% | 0 |
| 2021 | $289K | $181K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.